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It has been well established  that  the expression of a  particular  idiotype  (Id) ~ on 
antibodies  of a  given  specificity  is  often  linked  to  the  Igh-C  gene  complex  that 
determines the allotype markers of the Ig heavy chain constant  region  (l).  This has 
been particularly well documented in the anti-a(1-3) dextran (Dex) system which in 
fact serves as a  model reference system for this rule (2, 3).  Previous studies have thus 
indicated  that BALB/c  (Igh-C  a)  mice immunized with Dex B1355  [35%  a(1-3), 8% 
a(1-4),  and  57%  a(1-6)]  (4)  respond  with  ;kl-bearing  antibodies  directed  almost 
exclusively against the a(1-3) linkage (2). As much as 50% of these antibodies express 
the cross-reactive idiotype (IdX)  (5)  that has been defined with reference to a(1-3) 
Dex-binding BALB/c myeloma and hybridoma proteins (6). The structural correlates 
of this Id have been recently defined by a comparison of the amino-acid sequence of 
the  heavy chain  variable region  (Vn)  of a  panel  of IdX-positive and  IdX-negative 
a(1-3) Dex-binding myeloma and hybridoma proteins from BALB/c mice (6). These 
elegant studies have identified  two amino acids in positions 54 and 55 of the second 
V~ hypervariable region which determine ldX expression. 
The  strict  linkage  of IdX expression  with  the  Igh-C  ~ allotype  marker has  been 
demonstrated  by  the  incapacity  of mice  of other  heavy chain  linkage  groups  to 
synthesize anti-a(l-3)  Dex antibodies expressing this Id (2, 3). For example, C5781/6 
(Igh-C  ~') mice do not respond with detectable amounts of such antibodies. Their anti- 
a(1-3)  Dex  antibodies  bear  the  i¢  chain  in  the  primary  response  to  B1355,  and 
although they switch to ~l-bearing antibodies when hyperimmunized, these antibodies 
still do not express IdX (7).  It has been proposed that this immune status reflects an 
absence of the structural V,  Dex gene in these mice (7). In contrast, this gene would be 
present in all Igh  a haplotype strains, where it codes for IdX. 
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Related  studies  in  other  idiotypic  systems  indicate  however,  that  these  relations 
may not always obey strict rules (8, 9). The nonexpression of gene products may only 
be  apparent  when  they are  probed  by standard  immunization  procedures.  Mecha- 
nisms  based  on  Id  recognition  (10)  may  in  some  instances  activate  clones  that 
otherwise  remain  silent  or nonexpressed  (11-14).  In some  idiotypic  systems  in  the 
mouse, recent  studies  have demonstrated  that  after immunization  by anti-Id  it  was 
possible  to induce detectable  amounts of Ig (13)  or antibodies  (11,  12)  expressing  a 
reference Id in animals that could not express this Id upon conventional immunization 
with antigen. 
In  the  present  study  we  tested  this  approach  using  as  a  model  the  a(l-3)  Dex 
system.  Our results  indicate  that  substantial  amounts of ~t~-bearing,  IdX-positive Ig 
(Ab3), and a(l-3)  Dex-binding antibodies  (Abl') appear in C.B20 and C57B1/6 (Igh- 
C b) mice after treatment with rabbit anti-IdX antibodies  (Ab2). Contrary to BALB/ 
c mice immunized with Dex B1355, a  significant fraction of this response was of the 
IgG1 class.  The purified  C.B20 Abl' antibodies  differed  however from the  BALB/c 
antibodies  (Abl)  in  Dex-binding  specificity,  and  the  IdX-positive  IgG1  antibodies 
expressed the Igh4  b allotype determinants. 
Materials  and Methods 
Mice.  C57B1/6 and C57B1/10 (Igh-C  b) mice were obtained from the Centre de sfilection des 
animaux de laboratoire, Orlfians, France. The C.B20 (Igh-C  b, H2  d) congenic strain was obtained 
from Dr. M. Potter, National Cancer Institute, National Institutes of Health, Bethesda, MD. 
BALB/c (Igh-C  a, H2  d) and SJL/J (Igh-C  b) mice were obtained from our breeding facilities  at 
the Institut de Recherche Scientifique sur le Cancer. BAB/14 (Igh-C  b) mice were provided by 
Dr. M. Seman (Institut Jacques Monod, Paris).  Mice aged 12-15 wk were used in this study. 
Antigens.  Dex B1355  [35% a(1  3), 8% a(l-4), and 57% a(l-6)]  (4) was obtained from Dr. 
Allene Jeanes  (Northern  Regional  Research  Laboratory, U.  S.  Department  of Agriculture, 
Peoria, IL). Dex B512  [96% a(1-6), 4% ~  (1-3)]  (4) was obtained from Pharmacia, Uppsala, 
Sweden. Dextrans B742L, B742S(C3R), B1501S,  B1498S,  B1255, B1375,  and B1254S(Id) were 
kindly donated by Dr. E. A. Kabat, College of Physicians and Surgeons, Columbia University 
NY.  Panose  [a(1-6),  a(1  4)]  was  purchased  from Sefochem Fine  Chemicals,  Paris,  France. 
Escherichia  coil,  strain  B  was  purchased  from  Sigma  Chemical  Co,,  St.  Louis,  MO,  and 
concanavalin  A  (Con  A)  from  Serva  Feinbiochemica  GmbH  &  Co.,  Heidelberg,  Federal 
Republic of Germany (FRG). 
Myeloma and Hybridoma Proteins.  The a(1-3)  Dex-specific MOPC-104E  (M104E)  and J558 
myeloma proteins were  maintained  in our laboratory by subcutaneous  transfer of BALB/c 
mice. The proteins were purified from ascites  fluids by immunoabsorption on columns of Dex 
B 1355-Sepharose as described previously (15). The following myeloma and hybridoma proteins 
were generous gifts from various sources. 
The BALB/c a(1-3) Dex-binding hybridoma proteins Hdexl, Hdex3, Hdex8, Hdex 12, and 
Hdexl4 were obtained from Dr. B. Clevinger, Washington University School of Medicine, St. 
Louis, MO.  The proteins were purified  from ascites  fluids on columns of B1355-Sepharose. 
Purified W3129, a  BALB/c a(1  6)  Dex-binding myeloma protein, was from Dr. M. Scharff, 
Albert Einstein College of Medicine, NY. The purified inulin-binding myeloina protein J606 
was from Dr.  M.  Cohn, Salk  Institute,  San Diego, CA. Ascitic fluids containing the B(1  6) 
galactan-binding proteins X24, X44, and J539, the a(l  3)  Dex-binding protein TEPC-1072, 
and  the phosphorylcholine (PC)-binding protein  HOPC-8 and TEPC-15 were from Dr.  M. 
Potter. The PC-binding proteins were purified on a  column of cytidine 5'-diphosphocholine 
coupled to AH-Sepharose as  described  (16).  Purified  (4-hydroxy-3-nitrophenyl)acetyl (NP)- 
binding hybridoma proteins B1-8 and $43 were from Dr. K.  Rajewsky, Institut  fur Genetik, 
Koln, FRG. Ascites fluids containing the p-azophenylarsonate (Ar)-binding hybridoma protein 
36-65, 45-49, 44-1-3, and 31-65 were from Dr. M. N. Margolies, Massachusetts General Hospital, 
Boston, MA; the hybridoma proteins 91A3 and 93G7 were from Dr. J. D. Capra, University of PENE  ET  AL.  1575 
Texas,  Dallas,  TX,  and  hybridoma  R16-7  was  from  Dr.  A.  Nisonoff,  Brandeis  University, 
Waltham,  MA. These proteins were purified on columns of protein A-Sepharose. The pH of 
the etuting buffer was optimal for the respective classes of these proteins, as specified by Ey et 
al.  (17).  Purified UPC-10 was purchased from Litton Bionetics Inc., Kensington, MD. Ascites 
fluids containing the Igh4  b myeloma protein MOPC-245  (M245)  was from Dr. M. Potter. The 
protein was purified on a  column of protein A-Sepharose (17). 
Purification of  Induced Anti-c~(1-3) Dex Antibodies.  Dextran B 1355- or Ab2-induced antibodies 
were purified on mini-columns consisting of 1-ml capacity disposable plastic tips packed with 
200-500 ~1 of B1355-Sepharose  or B512-Sepharose gels. After passing through 0.2-1  ml of the 
test serum and washing until OD (280 nm) was ~<0.02, the bound antibodies were eluted with 
0.2 N  glycine buffer, pH 2.8, and collected into 2% bovine serum albumin, 0.05 M  phosphate 
buffer (BSA-PO4), pH 8.0. All procedures were carried out at 4°C. 
Anti-IdX Antibodies.  An anti-IdX reagent specific for the public Id shared  by IdX-positive 
a(l-3)  Dex-binding antibodies was prepared from the serum of rabbit 314 immunized with the 
J558 myeloma protein. Antiisotype antibodies were removed by absorption  with the following 
myeloma  proteins  coupled  to  cyanogen  bromide-activated  Sepharose  4B:  Fab  MOPC-173 
(M173)  (y2~, ~¢); MOPC-21  (M21)  (y~, x); HOPC-1  (yz,, h~);  HOPC-8  (a, x); A2  (y~, x). The 
purification  of Fab  M173,  M21,  HOPC-1,  and  A2  was  as  described  elsewhere  (14).  The 
antibodies  in the effluent serum were purified on a  column of M104E-Sepharose.  They were 
dialyzed  against  phosphate-buffered  saline  and  concentrated  to  3  mg/ml  on  Amicon  CF50 
membranes (Amicon Corp., Danvers, MA). Some batches of antibodies were reabsorbed on the 
HOPC-1  column to remove residual anti-X~  antibodies. 
The  idiotype-binding  capacity  (IBC~0)  of these  antibodies,  as  determined  by  the  indirect 
precipitation method described by Kuettner et al. (18), was 0.77 IBCs0//.tg of purified antibodies. 
Binding-site  inhibition  assays  indicated  40%  inhibition  by Dex B1355  of the binding of 125I- 
labeled  J558  to  microplates  coated  with  these  antibodies.  Dex  B512  or  panose  were  not 
inhibitory. 
Allogeneic  anti-Id  antibodies  were  prepared  by  immunizing  C57B1/6  mice  with  J558 
myeloma protein coupled to the keyhole lympet hemocyanin  (KLH)  (19).  The serum was first 
absorbed  on a  column of HOPC-8  (a, tc)-Sepharose to remove anti-Igh2 a antibodies,  and the 
antibodies were purified on a  column of J558-Sepharose.  75%  of the antibodies were directed 
to the J558 IdI, and 25% to the J558 IdX, as determined in an indirect hemagglutination assay 
(20)  using J558-  and  M104E-coupled  sheep erythrocytes.  Binding-site  inhibition  assays  gave 
75% inhibition by Dex B1355. The IBCs0 content was  1.86 IBC~0/#g of purified antibodies. 
A  syngeneic  BALB/c anti-J558  serum  was  a  gift of Dr.  P.  A. Cazenave,  Institut  Pasteur, 
Paris, France. The anti-J558 antibodies were purified on a column of J558-Sepharose. 
Rabbit Anti-Mouse  Heavy and Light  Chain Reagents.  Affinity-purified anti-K, anti-Fc/x, anti-y1, 
and anti-yz antibodies were obtained by previously described methods  (15).  Anti-,ka  antibodies 
were purified  from an anti-M104E  (#,  XI) serum.  The serum was preabsorbed  on columns of 
Fab M173, M21, and TEPC-183  (kt, ~¢) coupled to Sepharose, and the antibodies were purified 
on  a  column of HOPC-1.  Anti-y3 antibodies  were obtained  from an  anti-J606  ('/3, ~)  serum 
preabsorbed  on columns of Fab  M173,  M173, and M21, and  the antibodies were purified on 
a  column of FLOPC-21  (y3, ~¢). Anti-a antibodies were obtained from an anti-TEPC-15  (a, x) 
serum preabsorbed  on columns of Fab M173 and M21, and the antibodies were purified on a 
column ofJ558  (a, ~1). The specificity of these reagents was verified in indirect radioimmune 
binding  assays  (18)  using  a  panel  of myeloma  proteins  representative  of various  Ig  classes. 
Whenever required the purified reagents were reabsorbed  on appropriate columns. 
hnmunization  of Mice with Antiidiotype Antibodies.  Anti-IdX J558 antibodies  from rabbit  314 
were coupled to KLH by means of glutaraldehyde according to Bona et al. (19). One group of 
five C.B20 mice was immunized with Ab2-KLH. The mice received a  total of five injections, 
each containing 150 p.g of Ab2-KLH, the first in complete Freund's adjuvant (CFA), the second 
in incomplete Freund's adjuvant, and the remaining three in saline. Two other groups of C.B20 
mice, group 2 (five mice) and group 3 (eight mice), received only the first two injections of Ab2 
antibodies,  which were not coupled to KLH. The group  2 mice received  150 #g, and group  3 
mice, 100 p.g per injection. One group of five C57B1/6 mice received two injections of 150/~g of 
Ab2-KLH.  Equal  numbers  of control  mice in  each  group  were  identically immunized  with 1576  INDUCTION OF A J558 CROSS-REACTIVE IDIOTYPE-POSITIVE RESPONSE 
normal rabbit IgG (NRablgG)  (Pentex Biochemicals, Kankakee,  IL) absorbed  on a column of 
J558-Sepharose.  Lastly, one group of six C.B20 mice were immunized with two injections (80 
~tg) of allogeneic C57BL/6 anti-J558 antibodies coupled to KLH. 
Radiolabeting.  Myeloma  proteins  and  antibodies  were  radiolabeled  with  ~25! according to 
the method of Greenwood and  Hunter as modified by Cuatrecasas  and  Hollenberg (2t). The 
specific radioactivity ranged between 0.5 and 3 X  106 cpm//~g. 
Radioimmunoassay  (RIA)  for  the  IdX  Idiotype.  The  IdX  determinant  was  measured  by  a 
competitive inhibition RIA as described by Hansburg et al. (5).  In brief, serial dilutions of test 
serum or affinity-purified antibotties were tested for their capacity to inhibit the binding of 12sI- 
labeled  M104E  (4  ng,  ~4,000  cpm)  to  96-well  polyvinyl  chloride  microplates  (Dynatech 
Laboratories,  Inc.,  Alexandria,  VA)  coated  overnight  with  affinity-purified  anti-IdX  558 
antibodies  at  1.5  /xg/ml  in  10  /zg/ml  BSA-PO4.  After  overnight  incubation  at  37°C,  the 
microplates were washed and the radioactivity was estimated in a  gamma counter. The use of 
the heterologous M104E  protein  with the anti-J558 reagent  ensured  that  the assay  measured 
the IdX  determinant,  since the two a(1-3)  Dex-binding myeloma proteins  share  this  public 
determinant  but  differ  in  their  respective  IdI  determinants  (6).  The  amount  of  IdX  was 
estimated with reference to a  standard  inhibition curve constructed with unlabeled M 104E. A 
maximum of 60-70% of added counts were bound to the wells, with background binding ~0.5% 
of added counts. 
The IdX assay using the syngeneic anti-J558 antibodies was carried out by the competitive 
RIA described by Bosma et al.  (22).  This involved precoating the wells with MI04E  (0.25/.tg/ 
ml in  BSA-PO4),  followed by incubation  with anti-J558  antibodies  (1.5  ~g/ml  in 0.5%  BSA, 
pH 8.0). The remainder of the assay was performed as described above. 
b  a  b  RIA for the Igh4  and ]gh4  Allotype.  Igh4  allotype  determinants  were  estimated  using  a 
competitive RIA described  by Bosma et  al.  (22).  Microplates  were coated  with  10/_tg/ml  of 
M245  (Igh4 b) in BSA-PO4 followed by a 3 d incubation with a  1:40 dilution of a BALB/c anti- 
C57B1/6 Ig serum (a gift of Dr. M. Bosma, Fox Chase Institute, Philadelphia, PA). Radiolabeled 
M245  (2.5  ng, ~25,000 cpm) was added together with dilutions of test sera. A  standard  curve 
was  constructed  with  unlabeled  M245.  The  microplates  were  incubated  overnight  at  37°C, 
washed, and the radioactivity was estimated. 
For Igh4  a allotype determinants, microplates were coated overnight with specifically purified 
C57B1/6 anti-BALB/c Igh4  a antibodies  (6 btg/ml in BSA-PO4). Myeloma protein  M21  (Igh4  a) 
was used as the standard  and radiolabeled ligand (4 ng, ~4,000 cpm). From here on, the assay 
was carried out as above. 
RIA for  Anti-v~(1 3)  and  Anti-o~(l-6)  Dex  Antibodies.  The  titer  of  these  antibodies  was 
estimated  by  a  solid-phase  binding  assay  on  96-well  microplates  as  descr/bed  in  detail  by 
Geckeler et al. (23). For anti-a(l-3) determination, serial dilutions of sera or purified antibodies 
and  the  M104E  myetoma  protein  standard  (concentration  range,  0.31-25  ng/t00  #1)  were 
incubated  in duplicate (18 b, 24°C) on plates coated with 200/sg/m[ of Dex BI355_ This was 
followed by a 6-h incubation at 37°C with a predetermined saturating dose of 12r'I-labeled anti- 
)11 antibodies (15 ng/100 #1, ~30,000 cpm). Independent experiments using 12~I-labeled  M 104E 
or J558 indicated that  ~75% of the added counts were bound to the B1355-coated  plates. 
For  anti-a(l-6)  determination,  B512-coated  plates  were  used,  and  the  standard  was  the 
W3129 (anti-a(l-6) Dex myeloma protein). In this case, ~2~I-labeled  anti-~ antibodies were used 
in place of the anti-N~  reagent. 
The values were read on the linear portion of the standard binding curves and were expressed 
as #g/ml of anti-Dex antibodies. Threshold detectability of antibodies in the two assays was 0.5 
/Lg/ml of serum.  Background  binding  (omission  of the  sera  or Dex)  was  ~2%  of the added 
radiolabeled anti-light chain antibodies and was substracted  from all values. 
RIA for  Class Composition of Purified Anti-Dex Antibodies.  Whereas  the  preceding  assay  was 
designed to measure the total amount of either )~l-bearing or K-bearing anti-Dex antibodies, the 
present  assay was designed to determine the relative heavy chain class representation  of these 
antibodies.  This assay was essentially similar to that  above, except that  the antibodies bound 
to the Dex-coated plates were detected using an excess of I25I-labeled heavy chain class-specific 
reagents. The percentage of each antiisotype bound was calculated from the following formula: 
[(nanograms I25I-antiisotype bound per milliliter of antibodies -  background)/(nanograms  ~2aI- PENE  ET  AL.  1577 
anti-(y1  +  )'2 +  )'a +  a  +  ~)  bound  per milliliter of antibodies  -  background)]  ×  100.  The 
percentage of K-bearing anti-Dex antibodies was calculated as follows: [(nanograms  ~SI-anti-K 
bound  per  milliliter of antibodies  -  background)/(nanograms  l~SI-anti-(,¢  +  ?q)  bound  per 
milliliter of antibodies -  background)]  X  ~00. The percentage of~.~-bearing aatLDex antibodies 
was calculated  as follows: [(nanograms  l~S[-anti-~.i  bound  per milliliter of antibodies -- back- 
ground)/(nanograms  12SI-anti-(g  +  ~t)  bound  per milliliter of antibodies  -- background)]  x 
100. 
RIAfor Class Composition ofAb3 Ig.  This was carried out using a microplate-binding assay as 
described  above  for  the  class  composition  of antibodies,  except  that  the  microplates  were 
precoated with rabbit anti-IdX 558 antibodies (1.5 #g/ml in BSA-PO4). Before incubation, the 
test sera were absorbed on columns of Dex B 1355 and B512 to remove anti-Dex antibodies and 
additionally with  NRabIgG-Sepharose gels to remove anti-rabbit  IgG antibodies.  Such  anti- 
bodies  were  present  in  large  amounts  in  all  mice  immunized  with  the  rabbit  Ab2.  Their 
thorough  elimination  was  essential  in  this  assay  and  was  verified in  each  experiment  by  a 
parallel  incubation  on  NRabIgG-coated  wells  (control  binding).  The  percentage  of each 
antiisotype bound per milliliter of test serum was calculated from the same formulas as used for 
the anti-Dex antibodies  (see above). 
Results 
Specificity  of the  Anti-IdX  Antibodies.  The  specificity  of  the  rabbit  anti-IdX  558 
reagent was verified using as competitors a  panel of myeloma and hybridoma  proteins 
that  have  various antigen-binding  activities.  As can be seen  in  Fig.  t, only the IdX- 
positive a(1-3)  Dex-binding myeloma and hybridoma  proteins M  104E, J558, Hdex 1, 
and  Hdex3  completely inhibited  the binding  of 12SI-labeled M104E  to  anti-IdX  558 
antibodies,  whereas  the  IdX-negative  hybridoma  proteins  Hdex8  and  Hdexl4  were 
not  inhibitory.  Previous  work  by  Clevinger  et  al.  (6)  has  provided  the  structural 
correlates  of this  idiotype.  Amino  acids  in  positions  54  and  55  in  the  second  VH 
hypervariable  region were identified as immunodominant  residues  determining  IdX 
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FIO.  1.  Specificity ofanti-ldX 558 antibodies using IdX-defined (6) myeloma and hybridoma ~t(1- 
3) Dex-binding proteins and M 104E pepsin fragments. The relative inhibitory power of the proteins 
was measured in a competitive RIA as described in Materials and Methods. Proteins J558, M 104E, 
Hdexl, Hdex3, and Hdexl2 are IdX-positive (6, and B. Clevinger, private communication); protein 
Hdex8  has  20% relative IdX expression  (6)  and  protein  Hdex14  is IdX-negative (B.  Clevinger, 
private communication). Note that in the present assay, Hdex8 typed as IdX-negative and Hdexl2 
as having only 10% IdX expression  relative to the M104E ligand.  This loss of idiotype expression 
may have resulted from some denaturation during purification on the B 1355-Sepharose column (see 
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expression. The present reagent is thus similar to the one used by Clevinger et al.  (6) 
which allowed the authors  to distinguish IdX expression on these  monoclonal anti- 
bodies, 
The specificity of the reagent was further tested by using as competitors a panel of 
Ar-, NP-,  galactan-,  PC-, and  inulin-binding  myeloma and  hybridoma proteins  as 
well  as  a  panel  of 220 ascites  fluids containing various myeloma proteins.  A  single 
ascites fluid was found inhi'bitory. This contained protein TEPC-1072, a #, X1 weak 
anti-c~(l-3)  Dex-binding myeloma protein (M. Potter, personal communication). 
The subsequent experiments were designed to test the in vivo functional properties 
of these antibodies with respect to their capacity to induce an IdX-positive response 
in C57B1/6 and C.B20 mice. 
Induction of ldX-positiee tg in C. B20 and C57Bl/6 Mice.  Groups of C.B20 and C57B1/ 
6 mice (23 mice in all; see Materials and Methods) were injected with rabbit ant~-IdX 
558  (Ab2)  in CFA. The controls consisted of equal  numbers of mice  injected  with 
NRabIgG. 7 d after the last injection, the sera of these animals were tested in the IdX 
assay,  and  the  results  are  shown in  Fig.  2.  The sera  of all  mice  that  received  Ab2 
completely  inhibited  the  binding  of  125I-labeled  M104E  to  anti-IdX  558-coated 
microplates, while no significant inhibition was obtained with either their pre-immune 
sera or the sera of mice immunized with NRablgG. Similar results were obtained in 
an IdX assay that used syngeneic anti-J558 antibodies (not shown). 
In view of the early collection time of the sera,  there remained  a  possibility that 
residual  rabbit  anti-IdX was responsible for the inhibitions observed. Indeed, we as 
well as others (24),  have shown that anti-ld antibodies successfully compete with the 
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F1o.  2_  Expression of IdX on purified antibodies and sera from anti-IdX 558-treated C.B20 and 
C57B1/6 mice. The competitive RIA for IdX is described in Materials and Methods. Dotted lines, 
purified antibodies; full lines, whole sera. (O), M104E ligand; (O), purified C.g20 anti-a(1-3)  Dex 
antibodies (Abi'), pooI of days 42-63  (see Fig. 4);  (+), C.B2O anti-a(l-6)  De× ant{bodies purified 
from the same pool; (×), C.B20 anti-a(l-6) Dex antibodies purified from control NRabIg~G-injected 
mice, days 42-63 (see Fig. 4);  (V), whole C.B20 sera, pool of days 42-63 (see Fig. 4); (~), same pool 
absorbed on B [ 355-Sepharose; (0), whole C.B20 sera, day 7 after the last injection of B 1355-Con A 
(see Fig.  4);  (&),  pre-immune C.B20  serum  (pool of five mice);  (IJ), C.B20  whole sera from the 
NRabIgG-injected control group  (see Fig. 4);  (©),  whole C57B1/6  sera (pool of five mice), day  7 
after the  last  injection of Ab2  (see Fig. 4);  (ZX), pro-immune C57B1/6  serum  (pool of five mice); 
(1~, whole C57B1/6 serum from the NRabIgG-injected control group (see Fig. 4). PENE  ET AL.  1579 
radiolabeled  ligand  in  such  assays.  Independent  measurements  of  residual  Ab2 
administered  as two 23 #g injections  per mouse of 12~I-Ab2  in CFA into six normal 
C.B20 mice, indicated a  rapid clearance from the serum; 30 ng/ml remained at 2 d, 
and 2 ng/ml remained at  7 d  after the last injection. 
In other experiments,  individual  sera were preabsorbed with myeloma proteins or 
rabbit  anti-mouse  antibodies  coupled  to  Sepharose  before  being  tested  in  the  IdX 
assay. The results shown in Fig. 3 indicate that whereas the M 173- and J558-Sepharose 
gels  removed  marginal  inhibitory  activity,  the  rabbit  anti-IdX  and  anti-~l  gels 
removed most of the inhibitory activity.  Some inhibitory activity was also removed 
by the anti-K and anti-a gels.  The results strongly suggest that  the small  amounts of 
residual  Ab2 did not compete in this assay since inhibitory activity would have been 
removed  by the J558,  not by the anti-IdX gel.  Rather,  these results  suggest  that  Ig 
expressing  a  ~1  chain  and  the  IdX  determinant  were  responsible  for  most  of the 
inhibition observed in the IdX assay. 
In all, these results indicate that ~l-bearing,  IdX-positive Ig were being generated 
soon after immunization with Ab2 antibodies. The titer and the kinetics of these IdX- 
positive  Ig in individual  weekly bleeds  are shown in Fig. 4.  It can be seen that  IdX 
levels,  undetectable  in pre-immunization  sera,  abruptly  reached  a  value of 100-300 
/~g/ml in C.B20 mice and 50-100 #g/ml in C57B1/6 mice 7 d  after the last  injection 
of Ab2 antibodies.  The titers remained  at  a  plateau  during the 6 wk  (C57B1/6)  and 
18 wk (C.B20)  periods  investigated. 
When  C.B20  mice  were  boosted  with  Dex  B1355-Con  A  18  wk  after  the  last 
injection of Ab2, they responded  with a  sharp  increase  in the IdX titer  (maximum, 
150-350 #g/ml).  This response however, was not observed in C57B1/6 mice (Fig. 4). 
Control sera never contained >0.5-1 #g/ml of the IdX Id, values that are within the 
limits of the sensitivity of the assay. 
The results  indicate  that  the amount  of IdX-positive Ig can be further  increased 
upon  boosting  with  B1355.  Similar  results  were  obtained  in  13  other  C.B20  mice 
o~ 
~Lt~ 
~4 
t 
L  I 
~6  t 
I00  i 
No.1  No.2  No.3 
Mouse 
No.4 
Fro.  3.  Absorption of anti-IdX  558 (Ab2)-treated C.B20 sera (day 42, see Fig. 4) with myeloma 
proteins, antiisotype and anti-IdX 558 antibodies coupled to Sepharose 4B. The experiments were 
done on four individual sera. 100 #1 of a serum dilution giving 60-80% inhibition in the competitive 
RIA for IdX were incubated  with 50 ~l  of the  indicated  Sepharose gels for  1 h  at  4°C.  The 
supernatants were then rethrated  to estimate the residual IdX content (see text). 1580  INDUCTION OF A j558 CROSS-REACTIVE IDIOTYPE-POSITIVE RESPONSE 
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FIG. 4.  Effect  ofanti-IdX 558 treatment on the serum anti-a(t-3) Dex, anti-a(l-6) Dex, and IdX 
responses of C.B20  (a)  and C57B1/6  (b)  mice.  Five  mice were treated  with anti-IdX  (C.B20  anti- 
Ab2), and five  control mice were treated with normal rabbit  IgG (C.B20  anti-NRablgG)  on  the 
days indicated  by the arrows (see Materials and Methods). On day  159 (C.B20  mice), and on day 
56  (C57BI/6 mice), the animals were boosted with B1355  in CFA according to (2)~ B1355-Con  A 
according to (7), or E. coli according to (44), Tbe antibody titer was estimated in a binding assay, 
and the IdX concentration by competitive RIA as described in Materials and Methods. Each point 
is the arithmetic mean -+ SD of individual determinations. PENE ET AL.  1581 
immunized with only two injections of anti-IdX antibodies that were not coupled to 
KLH (see Materials and Methods). 
Induction of IdX-positive Anti-a(l-3)  Dex  Antibodies (Abl')  in  C.B20  and  C57Bl/6 
Mice.  The finding of this strong IdX-positive response suggested that  some of the 
IdX-positive Ig carried a(l-3) Dex-specific activity. First, we tested the sera for total 
~l-positive anti-a(1-3)  Dex antibodies. The results of these experiments are shown in 
Fig. 4. 
Whereas  anti-a(1-3)  Dex  antibodies  were  not  detectable  in  significant  amounts 
(41  ~g/ml)  in either pre-immune bleeds or in the NRabIgG-treated control groups, 
such antibodies appeared in small but significant amounts in each animal pretreated 
with Ab2. The antibodies were detectable with a  delay of 1-3 wk with respect to the 
IdX-positive Ig. The titers ranged from 15 to 40/~g/ml in the three groups of C.B20 
mice and  from 2  to  5  /zg/ml  in  C57B1/6  mice.  In control  animals conventionally 
immunized with B 1355 alone, some C57B1/6 mice, but none of the other Igh-C  b mice, 
responded with high levels (30-100 #g/ml) of anti-a(1-3) Dex antibodies (not shown). 
However, as will be discussed  below,  these conventionally  induced  anti-a(1-3)  Dex 
antibodies differed from the Ab2-induced antibodies in IdX expressi.on, in agreement 
with a  previous study (7). 
These results indicate that immunization with Ab2 alone leads to the appearance 
of a  low, but significant ~k~-positive anti-a(1-3)  Dex response. The maximum titer of 
these antibodies is about one order of magnitude lower than the serum IdX titer. 
Second, in order to determine whether these anti-a(1-3)  Dex antibodies expressed 
the  IdX  determinant,  the  antibodies  were  affinity  purified  from  pooled  sera  on 
columns of B1355-Sepharose, as described in Materials and Methods. The sera were 
preabsorbed on B512-Sepharose columns to eliminate anti-a (1-6) Dex antibodies that 
served as controls. Anti-a(1-6)  Dex antibodies were also purified from control mice 
injected with NRabIgG. Each effluent serum fraction from these absorptions was also 
saved. 
Fig.  2 shows that purified C.B20 anti-a(1-3)  Dex antibodies completely inhibited 
the  binding  of 125I-labeled  M104E  to  rabbit  anti-IdX  558.  The  inhibition  curves 
overlapped with  the standard  M 104E myeloma protein  inhibition  curve, as well as 
with  hyperimmune  BALB/c  anti-a(1-3)  Dex antibodies.  This  inhibition  pattern  is 
suggestive of a  high  degree of idiotypic similarity.  The data  furthermore suggested 
that most, if not all, of these antibodies express the IdX idiotype. This was indicated 
by the  fact  that  the  inhibition  curves  varied within  a  factor of 0.8-1.2  in  terms of 
weight of added competitor compared to the M 104E standard. An idiotypic deficiency 
would  have been seen by a  more pronounced  shift of the curve to the right. Thus, 
Ab2-treatment generates an early IdX-positive anti-a(1-3)  Dex response. 
Anti-a(1-3)  Dex antibodies purified from C.B20 mice boosted with B1355-Con  A 
(Fig.  4)  were  indistinguishable  from  the  above  antibodies  in  IdX  expression.  In 
addition,  Ab2  pretreatment  in  some  way  appeared  to  sensitize  these  animals  to 
respond with  substantial  amounts of IdX-positive antibodies,  as the  antibody titer 
rose from an average of 20 to 30-150 btg/ml after B1355 boosting. In all,  10 pools of 
sera from three C.B20 groups that include pre- and post-B1355 boost bleeds and one 
pool from C57B1/6  mice (a pre-B1355 boost bleed)  were tested, with similar results. 
Control Al-positive anti-a(1-3)  Dex antibodies purified from conventionally immune 
C57B1/6  mice, some of which  responded with  up to 300 ~g/ml of antibodies,  were 1582  INDUCTION OF A J558 CROSS-REACTIVE IDIOTYPE-POSITIVE RESPONSE 
devoid of inhibitory activity in the IdX assay. 
Induction of ldX-positive  Ig and Anti-e~(1-3) Dex Antibodies in C.B20 Mice Immunized with 
Allogenezc Anti-J558 Ab2.  A  group of six C.B20  mice were injected  twice at  a  15 d 
interval  with  80 gg/ml  (150  IBCs0)  of anti-J558  antibodies  coupled  to  KLH.  The 
magnitude of the  IdX-positive Ig and  the anti-a(1-3)  Dex antibody responses was 
significantly lower in these animals compared with the groups immunized with rabbit 
Ab2.  Only four mice responded, with an average of 8/zg/ml of IdX-positive Ig first 
detected as late as 6 wk after the second injection of Ab2. IdX expression in these sera 
was  measured  in  the  IdX  assay  that  used  the  rabbit  anti-IdX  558  reagent.  Pre- 
immune sera contained no detectable IdX-positive Ig or anti-a(1-3)  Dex antibodies. 
Only two mice responded with low titers  (2-4/.tg/ml)  of )~l-positive anti-~(1-3)  Dex 
antibodies.  However,  all  mice  responded  with  anti-cffl-3)  Dex  antibodies  when 
boosted with B1355-Con A  11 wk after the last Ab2-injection, but still with low titers 
(average 9/*g/ml). It was difficult to purify sufficient amounts of these antibodies for 
the determination of their IdX expression. 
Induction of ldX-positive  Ig Devoid of Dex-binding Activity  (Ab3).  The presence of such 
molecules  was  suggested  by  an  inspection  of the  data  presented  in  Fig.  4  which 
indicated  a  several-fold greater  level  of total  IdX-positive Ig compared with  IdX- 
positive anti-a(1-3)  Dex antibodies, These Ig were assayed after thorough absorption 
of the sera on B 1355 and B512 columns. The effluents, which were verified as lacking 
detectable Dex-binding activity in a binding assay, were nevertheless found inhibitory 
in the IdX assay. The Ig differed, however, from the Ab 1' antibodies by the slope of 
their inhibition curve, which was suggestive of an idiotypic deficiency in spite of their 
capacity  to  completely inhibit  the  binding  of 125I-labeled  M104E  to  anti-IdX  558 
(Fig. 2). 
Independent calculations gave the following relative amounts of Ab3 Ig and Abl' 
antibodies in whole sera. In the pre-B 1355-Con A boost bleeds of C.B20 and C57B1/ 
6 mice, ~90% of the IdX-positive Ig represented Ab3.  In post-B 1355  boost bleeds of 
C.B20  mice Ab3  and Abl' were about equally  represented  among IdX-positive Ig, 
while  in  C57B1/6  mice  the  proportion  of Ab3  remained  at  90%  of the  total  IdX- 
positive Ig. For comparison, BALB/c hyperimmune sera contain only -3% of Ab3 Ig 
with the vast majority of the IdX-positive component being represented by the Abt 
anti-~(1-3)  Dex antibodies. 
Therefore, injection  of Ab2 appears to generate at least  two populations of IdX- 
positive Ig in  these Igh-C  b mice, Molecules  lacking detectable  Dex-binding activity 
are  defined  as  Ab3,  and  molecules  with  intrinsic  a(1-3)  Dex-binding  activity  are 
defined as Abl'. Both definitions are used with reference to previous studies  (24,  25). 
Effect of Ab2-treatment on the Anti-c~(1-6) Dex Response.  The responder status of Igh- 
C b mice with respect to the a(1-6)  linkage of Dex is now well established  (26,  27).  It 
was thus of importance to assess whether anti-IdX 558 administration had any effect 
on the quantity and quality of this response. 
As shown in Fig. 4 the pre-immune level of anti-cffl-6) Dex antibodies  (10-30/_tg/ 
ml)  increased  two to threefold whether  the C.B20  and C57B1/6  mice were injected 
with  Ab2  or  NRabIgG.  Boosting  with  B1355-Con  A  did  not  affect  the  relative 
antibody level, which rose to ~ 100/*g/ml in both groups. 
The  expression  of IdX  on  these  antibodies  was  examined  in  the  IdX  assay.  As 
shown  in  Fig.  2,  anti-a(1-6)  Dex antibodies  purified  from C.B20  mice treated  with P~NE ET AL.  1583 
Ab2 or NRablgG were not inhibitory. However, antibodies purified from four other 
pools of Ab2-treated mice (but from none of the NRabIgG-treated groups)  gave up 
to 70% inhibition at high concentrations (Fig. 2). 
Binding assays indicated that  these sera contained ~5% of anti-or(i-3)  Dex anti- 
bodies. Since, as mentioned above, all anti-a(1-3) Dex antibodies were IdX-positive, 
these results can be interpreted on the basis of a contamination by a small amount of 
copurified anti-a(1-3)  Dex antibodies  (Dex B512 contains 4% of a(1-3)  glucosidic 
linkages [4]). 
The  results  indicate  that  the  in  vivo administered  rabbit  anti-IdX  558  had  no 
significant effect on the normal course of the anti-a(1-6) Dex response. 
Specificity  of Abl'  Antibodies for  Various Dex.  The  finding  that  Abl'  antibodies 
expressed the  IdX  determinant  prompted a  study of their Dex-binding specificity 
using a panel of eight Dex having different glucosidic linkages compositions (4). 
In all, six serum pools or individual bleeds from Ab2-treated C.B20 mice, and one 
purified anti-a(1-3) Dex antibody sample were tested. The binding pattern obtained 
with  the  purified  antibodies  was  typical  of the  results  obtained  with  the  serum 
samples, and is shown in Table I. Also shown is the binding pattern of purified anti- 
a(l-3)  Dex antibodies  from hyperimmune BALB/c mice and  from conventionally 
hyperimmunized  C57B1/6  mice, as  well  as  the binding  of the  reference J558  and 
MI04E myeloma antibodies (28, 29). 
The  C.B.20  and  the  BALB/c  antibodies  bound  most  strongly  to  Dex  B1355, 
B1498S,  and  B1501S  compared  with  the  remaining  five  dextrans,  B742S  (C3R), 
B742L, B1375, B1255, B1254S(E).  However, the C.B20 antibodies could be distin- 
guished from the BALB/c antibodies in that they bound less strongly to these last five 
Dex. This is clearly evident from the calculations of their relative binding avidities. 
Table I also shows that the binding specificity of the J558 myeloma protein measured 
in the present assay is very similar to that of its reported specificity in a  precipitin 
assay (28). In contrast, purified )~l-positive IdX-negative conventional C57B1/6 anti- 
bodies have a  very different binding pattern;  they do bind to B1355, B1498S, and 
B1501S, but they do not bind at all to the remaining five Dex. 
An element to be considered in such comparisons would appear to be the degree of 
polymerization of the antibodies as documented by previous work (30). We have not 
detected significant differences in binding avidity in samples typed as high IgG1, low 
IgM vs. high IgM, low IgG 1 Ab 1' content (see below for the class composition of Ab 1' 
antibodies). 
These experiments indicate that the Dex-binding specificity of C.B20 Ab 1' can be 
distinguished from that of the BALB/c antibodies. The C.B20 antibodies are, however, 
more closely related to the BALB/c than to the IdX-negative C57B1/6 antibodies. 
Class  Composition of the Abl'  Antibodies  and Ab3 Ig.  Previous studies  on  the  class 
composition of anti-a(l-3)  Dex antibodies of BALB/c mice have demonstrated the 
striking class restriction of this response  (31, 32).  Since the IdX-positive Abl' anti- 
bodies were induced by a  procedure that  differed from conventional immunization 
with Dex, it seemed relevant to study their class composition. 
The main finding was that the heavy chain class composition of the Ab 1' antibodies 
was highly restricted. IgG1 together with IgM represented the bulk of the response, 
with IgG1 by itself as the major class representing 70% of the Abl' antibodies (Fig. 
5 a). This was in contrast to the BALB/c primary and hyperimmune anti-a(l-3) Dex F
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FIc.  5.  Class composition  of purified  C.B20  anti-a(1-3)  Dex antibodies  (Abl'), anti-a(1-6)  Dex 
antibodies and BALB/c anti-a(1-3) Dex antibodies (Abl). (a) Classes of anti-a(1-3) Dex antibodies. 
(b) Classes of anti-0t(1-6) Dex antibodies. C.B20 anti-Ab2:  anti-IdX  558-treated  mice  (see Fig.  4); 
C.B20 (anti-Ab2) anti-B1355-Con A: anti-IdX-treated  and B1355-Con A boosted mice (see Fig. 4); 
BALB/c anti-B1355:7 d  primary response;  C.B20  (anti-NRabIgG)  anti-B1355-Con A: NRabIgG- 
treated  mice  boosted  with  B1355-Con A  (see Fig.  4).  In C.B20  mice,  the two  anti-Dex  antibodies 
were purified  from the same sera (see text). 
response which  was principally  in  the IgM  class,  whereas IgG1  was  not  detectable 
(Fig.  5 a). 
After boosting of the C.B20 mice with B1355-Con A  (see Fig. 4), the proportion of 
the  IgGl  antibodies  fell  to  6-35%  of the  heavy chain  classes, and  was replaced  by 
IgM as the major class (Fig. 5 a). However, even then IgG1 still represented a sizeable 
proportion of the response. This class was not detectable in any of the a(1-6)  specific 
antibody  samples  purified  from  the  same  sera  (Fig.  5b),  or from  the  sera of mice 
injected with NRabIgG.  Here, the response was mainly in the IgM  class, with some 
IgG3.  As  to  the  light  chains,  )kl was  the  only  light  chain  type  found  on  the  Abl' 
antibodies, except for one C.B20 pool in which 20% of the response was composed of 
x  chains.  The  occurence  of a  ~¢  anti-a(1-3)  Dex  component  was  also  reported  on 
previous occasions (33, 34). 
The class composition of Ab3  Ig is shown in Fig.  6. This was determined on seven 
individual  C.B20 sera or serum pools from the post-B1355-Con  A  boost period.  The 
sera were preabsorbed on columns of B 1355 and B512, and on a column of NRablgG 
before being  titrated  on anti-J558-coated  microplates  (see Materials  and Methods). 
As  in  the  case  of  the  Abl'  antibodies,  these  IdX-positive  Ig  were  also  largely 
represented  by  the IgG1  class.  Taken  together,  these  results  indicate  that  the IgG1 
class represents a  major component of the C.B20,  C57B1/6 Abl', and Ab3 responses. 
Allotype Assignment of C B20 IgGt Abl" Antibodies.  The exclusive linkage of IdX Dex 1586  INDUCTION OF AJ558 CROSS-REACTIVE IDIOTYPE-POSITIVE  RESPONSE 
F[o.  6.  Relative  percentage  of isotype composition of Ab3  Ig  in  whole  sera  (see  text  for  assay 
procedure).  C,B20 (anti-Ab2)anti-B1355-Con A: anti-IdX-treated and B1355-Con A  boosted mice 
(see  Fig. 4) ; BALB/c anti-B 1355:  hyperimmune BALB/c anti-B 1355 serum pool. 
En 
r-  .  ,  ,  BALB/c  ser.  Igh-C~ 
55 
h-C b 
i  i  i I  L~  i  1  i I  i v  i,  i 
Serum  (~.  1/24300 1/8100  1/2700  1/900  lJ300  1/100  1/10 
Inhibitor 
Fto.  7.  Determination  of the  Igh4  allotype  of C.B20  anti-~(1-3)  Dex  antibodies  (Abl').  The 
Igh4  allotype is described in Materials and Methods. (O) and (El), purified  competitive RIA for the  h 
C.B20 Abl' antibodies from two  pools of five C.B20 Ab2-treated mice;  (&),  purified C,B20 Abl' 
antibodies from a  pool of six Ab2-treated and B1355-Con A-boosted mice. 
expression with Igh-C  a is now well established  (2,  3). It thus appeared paradoxical  at 
first hand that  this idiotype was found associated with Abl' antibodies  of C.B20 and 
C57B1/6  mice known to be Igh-C  b homozygous. The lgh-C  allotype of pre-immuni- 
zation  sera  of the  C.B20  mice  used  in  this  study  was  verified  by  Ouchterlony  gel 
diffusion  using  polyvalent  anti-Igh-C  a and  anti-Igh-C  b allogeneic  sera  and  all  were 
typed homozygous Igh-C  b. We next investigated  the allotype of purified IdX-positive 
IgG1 antibodies. C.B20 Abl' antibodies purified from two pre-B1355-Con A and from 
four post-B1355-Con A  boost pools  (see Fig. 4)  were tested in parallel  in an assay for 
the Igh4  b and  an  assay for Igh4  a allotype determinants.  The results  shown  in  Fig.  7 
indicate that the antibodies were inhibitory in the assay for the Igh4  u allotype. There 
was no detectable  inhibition  in  the Igh4" allotype assay  (not shown).  This  indicates PENE ET AL.  1587 
that the IgG1 component of the Abl' comes entirely from the Igh-C  b haplotype. 
A possible inhibition by contaminant normal serum IgG1 in these experiments was 
excluded by the following. Several Abl' antibody pools, chosen for high  (80%)  IgG1 
antibody content, were divided into equal aliquots and absorbed with anti-x, anti-hi, 
or anti-IdX 558 antibodies coupled to Sepharose. The supernatants were then retested 
in  the allotype assay. The allotype inhibitory activity was completely removed only 
with the anti-ha and the anti-IdX gels, but to no significant extent by the anti-x gel 
(not  shown).  This then  strongly suggested that  all of the  IgG1  antibodies  typed as 
Igh4  b expressed the IdX determinant. 
Discussion 
The essential findings reported here show that the C.B20 and C57B1/6 mice respond 
with sizeable IdX-positive Ig (Ab3) and IdX-positive anti-a(1-3) Dex antibody (Ab 1') 
components after injections of rabbit anti-IdX 558.  The antibodies were defined as 
Abl' because of their idiotypic relatedness with the responder BALB/c IdX-positive 
anti-a(1-3) Dex antibodies (Ab 1), in analogy to a previously established nomenclature 
(24, 25). The anti-IdX antibodies thus acted by altering the phenotype of the response 
of these animals to the a(1-3) Dex glucosidic linkage, since previous studies indicated 
that  conventional  immunization  with  Dex  B1355  leads  to  either  an  IdX-negative 
anti-a(1-3)  Dex response (2,  7)  or to no detectable response in C.B20 mice (present 
study). 
Le Guern  et  al.  (12),  Bona  et  al.  (11),  and  Hiernaux  et  al.  (35),  have similarly 
found that Ab2 can act by inducing an Id-positive antibody response in animals not 
expressing this Id upon conventional immunization. In all cases the Ab2-induced Id 
was  shared  by  antibodies  having  the  same  antigen-binding  activity  in  responder 
mouse strains.  Furthermore, a similar approach to ours, using heterologous Ab2, was 
reported by Miller  et  al.  (13).  When  pig Ab2 specific for an  Id  found on  BALB/c 
antinuclease antibodies were injected into B t0.D2 mice, the latter responded with Ig 
expressing  this  Id.  The  Id  was  absent  from  antinuclease  antibodies  induced  by 
conventional immunization of B 10.D2 mice with staphylococcal nuclease. 
It was particularly important to determine the IdX-specificity of the rabbit reagent 
used in the idiotypic characterization of the Abl', as a  previous work as well as the 
present study indicated that C57B1/6 mice can respond with high titers of hi-bearing, 
but  IdX-negative anti-a(1-3)  Dex antibodies after conventional immunization with 
B1355-Con  A  (7).  This was done by testing the anti-IdX reagent against a  panel of 
reference  anti-a(1-3)  Dex  myeloma and  hybridoma  antibodies  (6).  Only  the  IdX- 
positive antibodies were effective competitors in the IdX assay. Our reagent thus had 
a  similar IdX-specificity than that reported by Hansburg et al.  (5)  and by Clevinger 
et  al.  (6).  Additionally,  we  have  purified  conventional  C57B1/6  anti-a(1-3)  Dex 
antibodies using the protocol ofGeckeler et al. (7) and found these to be IdX-negative 
in  our  assay,  confirming  the  results  of  a  different  assay  (7).  The  conventional 
antibodies were thus clearly distinguishable from Ab 1' antibodies induced by Ab2 in 
the same strains of mice. We were thus confident  that, as far as idiotypic relatedness 
is concerned, the Ab2-induced Ab 1' were indistinguishable from the responder BALB/ 
c  Abl  and  the  reference  IdX-positive myeloma and  hybridoma  antibodies.  These 
results argue strongly for the existence of a  nonexpressed or "silent" anti-a(1-3)  Dex 
repertoire in Igh-C  b mice (36). 1588  INDUCTION OF A J558 CROSS-REACTIVE [DIOTYPE-POSITIVE RESPONSE 
In the assay for IdX-positive Ig in  whole sera it was important  to determine  the 
possible interference of any residual rabbit anti-IdX Ab2. Indeed, we and others (24) 
found  that  anti-ldX  can  combine with  the  radiolabeled  proband  ligand  and  thus 
mimic  the  effect  of  competitor  IdX-positive  molecules.  For  this,  the  sera  were 
preabsorbed with various immunoabsorbents before being tested for IdX expression. 
The inhibitory activity was not eliminated by the J558 absorbent, indicating little if 
any residual  rabbit Ab2. On the other hand, the elimation of inhibitory activity by 
the  anti-N1  and  anti-IdX  absorbents  indicated  that  IdX-positive  Ig  were  being 
measured in the IdX assay and furthermore that most of them bore the 7~1 light chain. 
In addition to Abl', the Ab2-treated C.B20 and C57B1/6 mice also responded with 
relatively large amounts of IdX-positive Ig (Ab3),  which  lacked detectable binding 
activity to Dex B1355 or B512. In contrast to Abl', they appeared to lack the full Id 
complement of the  reference J558  myeloma protein.  Ab3  Ig have been  reported  as 
either  anti-(anti-Id)  antibodies  (12,  25),  i.e.,  directed  against  certain  idiotopes  ex- 
pressed by the inducing Ab2 antibodies, or as Ig that express a part of the idiotopes 
present  on  responder  Abl  antibodies  (11,  24).  It  is  considered  that  Ab3  and  Ab2 
express complementary idiotopes  (11,  37).  As concerns  the  a(l-3)  Dex system,  the 
later definition  for Ab3 may be more appropriate, This is based on the finding that 
Ab3 successfully competed in an IdX assay using either a rabbit or a mouse anti-J558 
reagent,  seen  with  Ab3  induced  with  either  one  of the  anti-Id  reagents.  Similar 
findings  were reported  for Id-bearing Ig in  the staphylococcal nuclease system  (38) 
and in the p-azophenylarsonate (39)  system. The a(1-3)  Dex system also enabled us 
to include the light chain marker with which to define these molecules (2). With only 
one exception, all tested samples of Ab3 Ig were found to bear exclusively this light 
chain  type, which  additionally  suggested their strong molecular similarity with  the 
responder anti-a(l-3)  Dex antibodies.  Ab3  Ig have been  described  in  several other 
related studies in both the rabbit and mouse (12,  24,  25,  38, 40). The true identity of 
the  IdX-positive Ab3  Ig is  still  not  fully understood,  and studies  are in  progress to 
further characterize them. 
It is revealing that Abl' were detectable in C.B20 and C57B1/6 mice without prior 
intentional  immunization  with  Dex.  Similar observations were recently reported  in 
which  a  single injection of anti-Id led to the appearance of Ig with specific antigen- 
binding  activity  (39,  41,  42)  although  in  those  studies  the  animals  were  genetic 
responders. It has been proposed that an Id-positive response can be induced directly 
by anti-Id by reacting with regulatory idiotopes  (11)  expressed on the membrane of 
B cell precursors. The hypothesis further assumes that the antigen-specific precursors 
constitute  a  subpopulation  of a  larger  Id-positive  precursor  pool  (11,  43).  In  the 
present study an inductive role played by endogenous flora microorganisms can not 
be excluded. For example, intestinal coliform saprophytes carrying cell wall Dex (44) 
could also have contributed  to the induction  of Abl' by further expanding the Ab 1' 
precursors. The delayed appearance of Abl' with respect to Ab3 would be consistent 
with this proposition. A similar view was held by Wysocki and Sato (39)  in a study of 
the arsonate system. 
On the other hand, it can not be decided to what extent an internal image (10)  or 
a  homobody  (45)  effect  of anti-Id  influenced  the  induction  of Abl'.  In  previous 
studies, such properties of anti-Id were indeed described  (46).  The immunochemical 
characterization  of the  rabbit  and  allogeneic  anti-Id  (see  Materials  and  Methods) PlaNE ET AL.  1589 
indicated  that  for approximately equal  amounts  of IBCs0 injected  per animal,  the 
IdX  response  of  mice  receiving  the  allogeneic  anti-J558  was  erratic  and  of  low 
magnitude. In contrast, in all mice injected with the rabbit anti-IdX the response was 
more intense and rapid. To what extent this was related to the different relative anti- 
IdI J558  vs. anti-IdX specificities in the two anti-Id, or to their relative content  of 
anti-binding  site specificity  (homobody), is  not  known.  The response does however 
appear to correlate with  the  IdX-specificity content  in  the  two  reagents,  since  the 
rabbit compared to the mouse reagent was 100 and 25% IdX-specific, respectively. 
It is significant that the Abl' levels of the Ab2-treated and B1355-Con A-boosted 
C.B20  mice  did  not  reach  the  amounts  found  even  in  the  primary  conventional 
BALB/c response (~800 ~g/ml). One can assume that the Igh-Cb-linked nonexpres- 
sion  of IdX  in  these  mice  reflects  the  participation  of T  suppressor  cells  as  was 
described in other genetically linked nonresponse systems (19,  47). Thus, if specific T 
suppressor activity had been abolished by Ab3, as was shown  in the Id 460 system 
(19), only some of the T  cell activity may have been inactivated. In other words, only 
the  anti-IdX-receptor-bearing  T  cells  would  be  targets  of Ab3,  whereas  other  T 
suppressors, specific for IdX-negative precursors, would remain functional and actively 
suppress this arm of the anti-~x(1-3) Dex response. 
The early appearance of Ab3  1 wk after the second injection of Ab2, and the fact 
that a large fraction of this response was of the IgG 1 class, suggests an involvement of 
T  helper cells in the inductive process. The fact that IgG1 is a prominent component 
of many secondary responses  that  involve T  cell  help  (48)  and  is  strongly thymus 
dependent  (49)  further attests  to this possibility. Ab2-presensitization  of these mice 
appears to have changed  the nature of this TI-2 type response  (50)  into a  thymus- 
dependent response. 
Previous  studies  where  anti-Id  (13,  51)  or  Id  (52)  was  injected  in  vivo  have 
implicated the participation of T  helper cells. In the present system, the T  helper cells 
may recognize regulatory idiotopes (11) shared by Igh-C  a and Igh-C  b anti-a(1-3) Dex 
antibodies.  For example, Gleason and  KShler  (53)  have shown  that  PC-induced T 
helper cells recognize shared idiotopes on two PC-binding myeloma antibodies M167 
and  T15,  each  of which  is  specifically  distinguished  by  anti-Id  sera.  Suggestive 
evidence that C57B1/6  and  BALB/c  anti-a(1-3)  Dex antibodies  express regulatory 
idiotopes stems from recent  experiments by C. Victor and C.  Bona  (personal  com- 
munication)  who  achieved  the  total  suppression  of  anti-a(1-3)  Dex  synthesis  in 
C57B1/6 mice injected at birth with nanogram quantities of either monoclonal CD5- 
3 anti-IdX 558 or monoclonal EB3-7.2 anti-Id 558 antibodies. 
The finding that C.B20 mice used an Igh-C  b haplotype product for the synthesis of 
their IgG1 Abl' was not unexpected since these mice are homozygous for this heavy 
chain linkage group (3).  In view of the tight linkage of the heavy chain locus (54), it 
is conceivable that  the IgM and IgG3 class Abl' are likewise products of the same 
haplotype.  Based  on  the  well  established  linkage  of allotype  to  idiotype  of many 
antibody responses in the mouse (1,  3, 55), this suggests that the Vn  DeX gene product 
of these mice is coded by a different gene than that which codes for the VH  Dex product 
in BALB/c mice. The remarkably reproducible differences in Dex-binding specificity 
of the Abl' compared with Abl  is compatible with this hypothesis.  Relevant to this 
is  the  description  by  Lieberman  et  al.  (56)  of PC-specific  myeloma proteins  from 
BALB/c and C57B1/6 which  displayed minor Vn  framework structural  differences, 1590  INDUCTION OF A J558 CROSS-REACTIVE IDIOTYPE-POSITIVE RESPONSE 
and  could  be  distinguished  by  appropriate  anti-Id  sera.  The  VH  markers  of these 
antibodies behaved  as allelic variants  in  the  PC  response  of various  mouse  strains. 
The confirmation of the present  findings at  the hybridoma level should  add  to our 
understanding of regulatory processes. 
Summary 
The effect of IdX-specific rabbit and allogeneic antiidiotype antibodies (Ab2) was 
investigated in vivo in Igh-C  b mouse strains with respect to the induction of a  cross- 
reactive idiotype (IdX)-positive anti-a(1-3) Dextran (Dex) response. These C.B20 and 
C57B1/6  mice have an allotype-linked incapacity to respond with  IdX-positive anti- 
a(1-3)  Dex  antibodies upon  conventional immunization with  Dex  B1355.  7  d  after 
the  rabbit  Ab2  injections, IdX-positive Ig  (Ab3)  and  IdX-positive anti-a(1-3)  Dex 
antibodies (Ab 1') were detected in the sera of each tested mouse. The affinity-purified 
Abl'  were idiotypically indistinguishable from  reference BALB/c IdX-positive mye- 
loma  proteins  and  BALB/c  anti-a(1-3)  Dex  antibodies  (Abl)  in  a  competitive 
inhibition radioimmunoassay, while Ab3 Ig appeared idiotypically deficient and did 
not bind to Dex. The response to the a(l-6)  linkage of Dex was not affected in these 
mice. A  large fraction of the Abl'  and Ab3 responses of both  mouse strains were of 
the  IgG1  class.  The  Abl'  antibodies  differed  from  BALB/c  Abl  by  lower  relative 
binding to five of eight tested Dex, and by expressing the Igh4  b allotype determinants 
on the IgG1 antibodies. This study identifies the products ofa V, Dex gene that appears 
to be under regulatory control in the Igh  b mice. Its association with the b  haplotype 
suggests that this gene may differ structurally from the BALB/c V. I~ex gene. 
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